SENSEX NIFTY
Cadila Healthcare > Company History > Pharmaceuticals > Company History of Cadila Healthcare - BSE: 532321, NSE: CADILAHC
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - Cadila Healthcare
Cadila Healthcare
BSE: 532321|NSE: CADILAHC|ISIN: INE010B01019|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Oct 23, 17:00
1377.50
10.3 (0.75%)
VOLUME 1,637
LIVE
NSE
Oct 23, 17:00
1376.85
7.2 (0.53%)
VOLUME 9,934
Company History - Cadila Healthcare
1995
 
 - The Company was incorporated as Cadila Healthcare Private Ltd. on
 May 15, under the company act, 1956 and subsequently the Company was
 converted into a public company and then renamed as Cadila Healthcare
 Ltd. effective from Juy 17, 1996.
 
 - The name Cadila shall be used only for Cadila Healthcare Limited
 (Zydus Cadila), Cadila Pharmaceuticals Limited (CPL) and Cadila
 Laboratories Limited (CLL).
 
 - The Company is flagship company of Zydus Cadila Group.
 
 - The Company's operations include pharmaceuticals (human
 formulations, veterinary formulations and bulk drugs); diagnostics,
 herbal products, skin care products and other OTC products.
 
 - The Company has 6 subsidiaries Indon Healthcare Ltd., Zydus
 Pharmaceuticals Ltd., Zudus Aqrovet Ltd., Zoom Properties Pvt.  Ltd.,
 Zydus International Pvt. Ltd., Ireland and Zydus Healthcare S.A. (Pvt)
 Ltd., South Africa.
 
 - Zydus Cadila signed an agreement with Anda Biologicals, France, for
 Marketing and distribution of diagnostic kits.  Anda to appoint a max.
 of two distributors in India.
 
 1996
 
 - Zydus Cadila signed an agreement with Centeon L.L.C., USA and
 Centeon Pharama GMBH, Germany for Exclusive rights to sell and
 distribute plasma products in India and Nepal.
  
 - In May, Zydus Cadila signed an agreement with Acta Services Srl.,
 Rome for distribution of Diagnostic instrument Acto 1 Analyser manu.
 By Acta.
 
 - In June, Zydus Cadila signed an agreement with China Resources
 Gulin Pharma, Works, China, for exclusive supply of Artesunate
 Granules to Zydus Cadila.
 
 - In July, Zydus Cadila signed an agreement with Shimizu Chemical
 Corporation, Japan, for Marketing of specified products by Zydus
 Cadila in India.
 
 1997
 
 - A Scheme of Arrangement and Amalgamation was sanctioned by
 honorable High Court of Gujarat by order passed on May 2 issued on
 August 16th. 
 
 - Zydus Cadila would issued 1,48,423 fully paid-up equity shares of
 Rs 10/- each to the shareholders of Patel Group in exchange for the
 assets transferred to them of Transferor companies.
 
 - Zydus Cadila has also tied-up with Regional Research Laboratory
 Jammu, to develop Enzymatic Resolution for Paroxetine HCL and some
 other Enzymatic products.
 
 1998
 
 - In February, Zydus Cadila signed an agreement with Apotex SA Pty.
 Ltd. for manufacturer of Amoxycillin, Ampicillin, Co - trimoxazole,
 paracetamol.
 
 - Zydus Cadila has also entered into a joint venture with Korea Green
 Cross Corporation, Korea, to manufacture and market recombinant
 Hepatitis B vaccine in India.
 
 1999
 
 - In April, Zydus Cadila signed an agreement with Ethical Holdings
 Plc, Beta Pharma, and Ethical Pharma South America S.A. for Know-how
 Licence Agreement to manufacture, marketing and sell transdermal
 pharmaceutical formulations.
 
 - In September, Zydus Cadila signed an agreement with Cherry Valley
 Farms Ltd., UK for supply of vaccine eggs.
 
 - Zydus Cadila has entered into a 50:50 joint venture with Byk Gulden
 of Germany, a renowned, research-oriented Pharma company of Germany
 and the world-wide patent holder of the novel proton pump inhibitor,
 Pantoprazole.
 
 - During the year under report, the Company had issued 2,00,000 12%
 Cumulative Redeemable Preference shares of Rs. 100/- each fully paid
 to the members of the Company, which are redeemable at par on 1st
 July, 2001.
 
 - During the year under report, Indon Healthcare Limited and Zydus
 Aqrovet Limited, have become wholly owned subsidiaries of the
 company. 
 
 - During the year under report, the Company has undertaken to set up
 a new project for manufacturing the bulk drug-Losartan at Ankleshwar.
 
 
 - The Company laid the foundation for a new feed supplement plant, at
 Vatwa.  The feed supplement for poultry and cattle has been developed
 by tie company's R & D bio-tech department.
 
 - The Company has set up a joint venture company to manufacture the
 break-through molecule Pantoprazole.  The Company is also undertaking
 discovery research projects with Byk Gulden as a pan of the Joint
 Venture.
 
 - The Company has entered into a technical-cum-marketing tie-up with
 the Swiss Serum and Vaccine Institute, Berne, Institute to launch a
 range of vaccines in India.
 
 - The Company has entered into a joint venture with the Haffkine
 institute to undertake research in the field of human vaccine and
 equine sera.
 
 - A new State-of-Art Research & Development centre being set-up with
 the capital cost of approximately Rs. 25.00 crores in the Village:
 Moraiya. Taluka:Sanand, Dist.: Ahmedabad.
 
 - During the year under report the Company has launched several new
 products in the market : Vac Typh, HB Vac, Xylodac, Losartan, Losacar
 was the first to be launched in India & Matergam P.
 
 - The Company has set up manufacturing premises to manufacture the
 feed supplement - Improval at GIDC Vatwa.
 
 - Shir Pranlal Bhogilal was appointed as an additional Director of
 the Company with effect from 15th December, 1998 pursuant to Section
 260 of the Companies Act, 1956.
 
 - Shri Mukesh M. Patel Director of the Company retires by rotation
 and he is eligible for reappointment.
 
 - A new welfare policy has been introduced for employees of the
 Company.
 
 2000
 
 - The Company is setting up wholly owned subsidiaries abroad and
 plans to acquire overseas companies to market products.
 
 - The Company has entered into License Agreement for phased
 manufacture and technical know-how transfer with Swiss Serum and
 Vaccine Institute, Switzerland for the manufacture of Purified Cuck
 Embroy Vaccine.
 
 - The Country's fifth largest pharmaceutical company, is considering
 offering stocks to its employees through an employees' stock option
 scheme.
 
 - The Company has launched two drugs for the treatment of human
 immunodeficiency virus.
 
 - The Bulk Drugs at Ankleshwar in Gujarat has an ISO 9002
 certification for the manufacture and supply of a number of
 molecules.
 
 - Public Issue of 1,48,86,000 No. of Equity shares (Issue) of Rs 5/-
 each issued for cash at a premium of Rs [] per share aggregating Rs
 [] million.  The Issue includes a Book Built Portion of 1,33,97,400
 No. of equity shares and a Fixed price portion of 14,88,600 No. of
 Equity
 Shares.
 
 - Authorised share capital of the Company is Rs 500 million divided
 into 9,00,00,000 No. of Equity Shares of Rs 5/- each and 5,00,000
 Preference Shares of Rs 100/- each.
 
 - During the year under report, the Company has been recognise as a
 Prestigious Unit and granted adhoc eligibility for Sales Tax
 deferment by the Industries Commissionerate, Gandhinagar, under New
 Incentive Policy - Capital Investment Incentive to Premier/
 Prestigious
 unit scheme 1995-2000.
 
 - During the year under report Zydus Pharmaceuticals Limited and Zoom
 Properties Limited have become Wholly Owned Subsidiaries of the
 Company.
 
 - The Company has formed a JV Company in the name of Zydus Byk
 Healthcare Limited with an equal participation in collaboration with
 Byk Gulden Lomberg Chemische Fabrik GmbH, Germany, for manufacturing
 of Bulk Drugs, Formulations and R & D.
 
 - The Company has also formed a JV Company in the name of Sarabhai
 Zydus Animal Health Ltd. in collaboration with Ambalal Sarabhai
 Enterprises Ltd., Baroda, with an equal participation to carry on the
 business of animal health segments.
 
 - The company has also entered into a technical collaboration with
 Ethical Holdings of U.K. to manufacture and market transdermal
 patches in India.
 
 - The Company launched block-buster molecules Atorvastatin (Atorva),
 Lamivudine (Lamidac 100) and Celecoxib (Zycel), Meloxicam (Mel-OD)
 and Carvedilol (Carvil) during the year.
 
 - The company was the first to launch the anti-hypertensive drug
 Losartan in India.
 
 - Currently ranked 6th largest pharmaceutical company in India,
 Cadila Healthcare is one of the fastest growing pharmaceutical
 companies in the country.
 
 - It has also entered into a technical collaboration with Ethical
 Holdings of the UK to manufacture and market transdermal patches in
 India.
 
 - Zydus Cadilla has also entered into a technical collaboration with
 Ethical Holdings of the UK to manufacture and market transdermal
 patches in India.
 
 - Cadlia Healthcare (CHL) has signed an MoU with Rs 54 crore Recon
 Limited, whereby it will acquire all the 8 formulation brands of the
 Bangalore based comapny, as well as its distribution network. 
 
 - The new company, `Recon Healthcare Ltd' is now a subsidiary of
 Zydus Cadila with Zydus holding 90 per cent stake.
 
 - Cadila Healthcare Ltd is setting up wholly owned subsidiaries
 abroad and plans to acquire overseas companies to market products.
 
 - Cadila also launched zidovudine, which is imported and marketed
 under the brand name Zydowin. Zidovudine, commonly called AZT, is an
 AIDS-retardant drug made by Glaxo Wellcome.
 
 - Zydus Alidac, the marketing arm of Cadila Healthcare Ltd., has
 launched www.penegra.org.
 
 -The Ahmedabad-based Cadoila Healthcare has completed the phase-III
 clinical trials and the bioequivalence study of the wonder drug
 sildenafil citrate (Viagra).
 
 2001
 
 - Cadila Healthcare has signed a three year collaborative R&D
 agreement with Danish biotech company Pantheco in the field of
 anti-bacterials.
 
 - The neurosciences division launched by the company has introduced
 anxiolytic paroxetine for the first time in the country.
 
 - Cadila Healthcare Ltd has posted a 14.75 per cent increase in net
 profit at Rs 21.86 crore for the quarter ended September 30,
 2001.YEAR EVENTS 1995 
 
 - The Company was incorporated as Cadila Healthcare Private Ltd. on
 May 15, under the company act, 1956 and subsequently the Company was
 converted into a public company and then renamed as Cadila Healthcare
 Ltd. effective from Juy 17, 1996.
 
 - The name Cadila shall be used only for Cadila Healthcare Limited
 (Zydus Cadila), Cadila Pharmaceuticals Limited (CPL) and Cadila
 Laboratories Limited (CLL).
 
 - The Company is flagship company of Zydus Cadila Group.
 
 - The Company's operations include pharmaceuticals (human
 formulations, veterinary formulations and bulk drugs); diagnostics,
 herbal products, skin care products and other OTC products.
 
 - The Company has 6 subsidiaries Indon Healthcare Ltd., Zydus
 Pharmaceuticals Ltd., Zudus Aqrovet Ltd., Zoom Properties Pvt.  Ltd.,
 Zydus International Pvt. Ltd., Ireland and Zydus Healthcare S.A. (Pvt)
 Ltd., South Africa.
 
 - Zydus Cadila signed an agreement with Anda Biologicals, France, for
 Marketing and distribution of diagnostic kits.  Anda to appoint a max.
 of two distributors in India.
 
 1996
 
 - Zydus Cadila signed an agreement with Centeon L.L.C., USA and
 Centeon Pharama GMBH, Germany for Exclusive rights to sell and
 distribute plasma products in India and Nepal.
 
 - In May, Zydus Cadila signed an agreement with Acta Services Srl.,
 Rome for distribution of Diagnostic instrument Acto 1 Analyser manu.
 By Acta.
 
 - In June, Zydus Cadila signed an agreement with China Resources
 Gulin Pharma, Works, China, for exclusive supply of Artesunate
 Granules to Zydus Cadila.
 
 - In July, Zydus Cadila signed an agreement with Shimizu Chemical
 Corporation, Japan, for Marketing of specified products by Zydus
 Cadila in India.
 
 1997
 
 - A Scheme of Arrangement and Amalgamation was sanctioned by
 honorable High Court of Gujarat by order passed on May 2 issued on
 August 16th. 
 
 - Zydus Cadila would issued 1,48,423 fully paid-up equity shares of
 Rs 10/- each to the shareholders of Patel Group in exchange for the
 assets transferred to them of Transferor companies.
 
 - Zydus Cadila has also tied-up with Regional Research Laboratory
 Jammu, to develop Enzymatic Resolution for Paroxetine HCL and some
 other Enzymatic products.
 
 1998
 
 - In February, Zydus Cadila signed an agreement with Apotex SA Pty.
 Ltd. for manufacturer of Amoxycillin, Ampicillin, Co - trimoxazole,
 paracetamol.
 
 - Zydus Cadila has also entered into a joint venture with Korea Green
 Cross Corporation, Korea, to manufacture and market recombinant
 Hepatitis B vaccine in India.
 
 1999
 
 - In April, Zydus Cadila signed an agreement with Ethical Holdings
 Plc, Beta Pharma, and Ethical Pharma South America S.A. for Know-how
 Licence Agreement to manufacture, marketing and sell transdermal
 pharmaceutical formulations. 
 
 - In September, Zydus Cadila signed an agreement with Cherry Valley
 Farms Ltd., UK for supply of vaccine eggs.
 
 - Zydus Cadila has entered into a 50:50 joint venture with Byk Gulden
 of Germany, a renowned, research-oriented Pharma company of Germany
 and the world-wide patent holder of the novel proton pump inhibitor,
 Pantoprazole.
 
 - During the year under report, the Company had issued 2,00,000 12%
 Cumulative Redeemable Preference shares of Rs. 100/- each fully paid
 to the members of the Company, which are redeemable at par on 1st
 July, 2001.
 
 - During the year under report, Indon Healthcare Limited and Zydus
 Aqrovet Limited, have become wholly owned subsidiaries of the
 company.
 
 - During the year under report, the Company has undertaken to set up
 a new project for manufacturing the bulk drug-Losartan at Ankleshwar.
 
 
 - The Company laid the foundation for a new feed supplement plant, at
 Vatwa.  The feed supplement for poultry and cattle has been developed
 by tie company's R & D bio-tech department.
 
 - The Company has set up a joint venture company to manufacture the
 break-through molecule Pantoprazole.  The Company is also undertaking
 discovery research projects with Byk Gulden as a pan of the Joint
 Venture.
 
 - The Company has entered into a technical-cum-marketing tie-up with
 the Swiss Serum and Vaccine Institute, Berne, Institute to launch a
 range of vaccines in India.
 
 - The Company has entered into a joint venture with the Haffkine
 institute to undertake research in the field of human vaccine and
 equine sera.
 
 - A new State-of-Art Research & Development centre being set-up with
 the capital cost of approximately Rs. 25.00 crores in the Village:
 Moraiya. Taluka:Sanand, Dist.: Ahmedabad.
 
 - During the year under report the Company has launched several new
 products in the market : Vac Typh, HB Vac, Xylodac, Losartan, Losacar
 was the first to be launched in India & Matergam P.
 
 - The Company has set up manufacturing premises to manufacture the
 feed supplement - Improval at GIDC Vatwa.
 
 - Shir Pranlal Bhogilal was appointed as an additional Director of
 the Company with effect from 15th December, 1998 pursuant to Section
 260 of the Companies Act, 1956.
 
 - Shri Mukesh M. Patel Director of the Company retires by rotation
 and he is eligible for reappointment.
 
 - A new welfare policy has been introduced for employees of the
 Company.
 
 2000
 
 - The Company is setting up wholly owned subsidiaries abroad and
 plans to acquire overseas companies to market products.
 
 - The Company has entered into License Agreement for phased
 manufacture and technical know-how transfer with Swiss Serum and
 Vaccine Institute, Switzerland for the manufacture of Purified Cuck
 Embroy Vaccine. 
 
 - The Country's fifth largest pharmaceutical company, is considering
 offering stocks to its employees through an employees' stock option
 scheme.
 
 - The Company has launched two drugs for the treatment of human
 immunodeficiency virus.
 
 - The Bulk Drugs at Ankleshwar in Gujarat has an ISO 9002
 certification for the manufacture and supply of a number of
 molecules.
 
 - Public Issue of 1,48,86,000 No. of Equity shares (Issue) of Rs 5/-
 each issued for cash at a premium of Rs [] per share aggregating Rs
 [] million.  The Issue includes a Book Built Portion of 1,33,97,400
 No. of equity shares and a Fixed price portion of 14,88,600 No. of
 Equity Shares.
 
 - Authorised share capital of the Company is Rs 500 million divided
 into 9,00,00,000 No. of Equity Shares of Rs 5/- each and 5,00,000
 Preference Shares of Rs 100/- each.
 
 - During the year under report, the Company has been recognise as a
 Prestigious Unit and granted adhoc eligibility for Sales Tax
 deferment by the Industries Commissionerate, Gandhinagar, under New
 Incentive Policy - Capital Investment Incentive to Premier/
 Prestigious
 unit scheme 1995-2000.
 
 - During the year under report Zydus Pharmaceuticals Limited and Zoom
 Properties Limited have become Wholly Owned Subsidiaries of the
 Company.
 
 - The Company has formed a JV Company in the name of Zydus Byk
 Healthcare Limited with an equal participation in collaboration with
 Byk Gulden Lomberg Chemische Fabrik GmbH, Germany, for manufacturing
 of Bulk Drugs, Formulations and R & D.
 
 - The Company has also formed a JV Company in the name of Sarabhai
 Zydus Animal Health Ltd. in collaboration with Ambalal Sarabhai
 Enterprises Ltd., Baroda, with an equal participation to carry on the
 business of animal health segments.
 
 - The company has also entered into a technical collaboration with
 Ethical Holdings of U.K. to manufacture and market transdermal
 patches in India.
 
 - The Company launched block-buster molecules Atorvastatin (Atorva),
 Lamivudine (Lamidac 100) and Celecoxib (Zycel), Meloxicam (Mel-OD)
 and Carvedilol (Carvil) during the year.
 
 - The company was the first to launch the anti-hypertensive drug
 Losartan in India.
 
 - Currently ranked 6th largest pharmaceutical company in India,
 Cadila Healthcare is one of the fastest growing pharmaceutical
 companies in the country.
 
 - It has also entered into a technical collaboration with Ethical
 Holdings of the UK to manufacture and market transdermal patches in
 India.
 
 - Zydus Cadilla has also entered into a technical collaboration with
 Ethical Holdings of the UK to manufacture and market transdermal
 patches in India.
 
 - Cadlia Healthcare (CHL) has signed an MoU with Rs 54 crore Recon
 Limited, whereby it will acquire all the 8 formulation brands of the
 Bangalore based comapny, as well as its distribution network. 
 
 - The new company, `Recon Healthcare Ltd' is now a subsidiary of
 Zydus Cadila with Zydus holding 90 per cent stake.
 
 - Cadila Healthcare Ltd is setting up wholly owned subsidiaries
 abroad and plans to acquire overseas companies to market products. 
 
 - Cadila also launched zidovudine, which is imported and marketed
 under the brand name Zydowin. Zidovudine, commonly called AZT, is an
 AIDS-retardant drug made by Glaxo Wellcome.
 
 - Zydus Alidac, the marketing arm of Cadila Healthcare Ltd., has
 launched www.penegra.org.
 
 -The Ahmedabad-based Cadoila Healthcare has completed the phase-III
 clinical trials and the bioequivalence study of the wonder drug
 sildenafil citrate (Viagra).
 
 2001
 
 - Cadila Healthcare has signed a three year collaborative R&D
 agreement with Danish biotech company Pantheco in the field of
 anti-bacterials. 
 
 - The neurosciences division launched by the company has introduced
 anxiolytic paroxetine for the first time in the country.
 
 - Cadila Healthcare Ltd has posted a 14.75 per cent increase in net
 profit at Rs 21.86 crore for the quarter ended September 30, 2001.
 
 2002
 
 -Cadila Healthcare Ltd has informed BSE that at the meeting of the
 Board of Directors of the company held on August 20, 2002 it has been
 decided to issue/allot Secured Redeemable Non Convertible Debentures
 for an aggregate face value of Rs 700 million by private placement
 basis at an interest rate of 8.40% p.a.
 
 2003
 
 -Mr.UpenShah has been designated as the Company Secretary and
 Compliance Officer
 of Cadila Healthcare Ltd.
 
 -Zydus Cadila, the ahmedabad  based healthcare has bagged global
 marketing rights 
 of an anti-rabies vaccine of vaxirab a swiss company Berna Biotech.
 
 -Cadila Healthcare receives Mumbai High court approval for the scheme
 of amalgamation 
 with German Remedies Ltd and Zoom Properties Ltd.
 
 -Cadila Healthcare Ltd has acquired US base Alpharma Inc's French
 Subsidiary Alpharma
 SAS France for a consideration of Euro 5.5 million.
 
 -Mr.H.K.Bilpodiwala, Mr.H.Dhanarajgir and Mr.A.S Diwanji have been
 appointed as the 
 additional directors on the board of the company.
 
 -Zydus Cadila Healthcare Ltd has signed a pact with Schering AG,
 Germany which allows
 the Indian Pharmaceuticals major to market Schering's patented
 products in India.
 
 -Duphar Interfran, a subsidiary of Fermenta Biotech Ltd signed an
 agreement with
 Cadila Ltd for the sale of FBL's global patents of Chiral Building
 blocks and process
 teechnology for the manufacture of Lisinopril and Benazepril.
 
 -Zydus forges marketing pact with Schering
 
 2004
 
 -Zydus Cadila sets up Zydus Pharmaceuticals USA, Inc
 
 -Zydus Cadila inks strategic pact with Boehringer Ingelheim
 
 -Zyndus Altana Healthcare - the JV between Altana Pharma AG and
 Zyndus Cadila, has been accredited with the ISO 9001-2000
 certificate.
 
 2005
 
 - Zydus Cadila receives approval from the USFDA to market the
 anti-hypertensive drug, Atenolol, and an anti-infective drug,
 Clindamycin on 31 Jan and 1 Feb.
 
 -Zydus Cadila unveils 'Pitavastatin' to control cholesterol on 
 February 21, 2005
 
 -Cadila ties up with Tyco unit to sell generic drugs in US
 
 - Launches NuPatch - India's first indigenously manufactured
 Diclofenac transdermal patch for pain relief.
 
 -Cadila Healthcare & Mayne signs agreement to set up JVC to
 manufacture specialty oncology products
 
 -Cadila Healthcare - German Remedies launches Fludara Oral for
 Lymphocytic Leukaemia
 
 -Zydus Cadila receives tentative approval for Divalproex Sodium DR
 Tablets from US FDA
 
 -Cadila Healthcare receives approval for Promethazine Tablets from
 USFDA
 
 -Cadila Healthcare enters into JV with BSVL
 
 2006
 
 -Zydus Cadila forges alliance with French firm
 
 -Zydus Cadila receives USFDA approval for Simvastatin Tablets
 
 -Zydus Cadila to acquire Nutralite - India's largest selling
 cholesterol-free margarine
 
 -Sarabhai Zydus to roll out immuno-diagnostics kits
 
 -Cadila Healthcare has given the Bonus in the Ratio of 1:1
 
 2007
 
 -Cadila Healthcare Ltd on April 19, 2007 has announced the
 acquisition of Nippon Universal Pharmaceutical Ltd.
 
 - Cadila Healthcare Ltd has announced that its second overseas
 acquisition this year, the Company signed an agreement to acquire
 100% stake in Quimica e Farmaceutica Nikkho do Brasil Ltda.
 
 -Zydus Cadila acquires Nippon Universal, strengthens its presence in
 Japan
 
 -Zydus Cadila, the first to launch revolutionary anti-obesity drug
 Slimona in India
 
 -Zydus Cadila acquires Brazilian Company Nikkho
 
 2008
 
 -Zylus Cadila, Karo Bio to jointly develop new drugs
 
 -Zydus Cadila & Karo Bio of Sweden sign research agreement for a
 novel drug to treat inflammatory diseases
 
 -Zydus Cadila acquires Etna Biotech, a subsidiary of Crucell N.V. 
 
 -Zydus scores with first day launch of Venlafaxine Hydrochloride in
 the US 
 
 2009
 
 -Zydus Cadila announces research collaboration to discover and
 develop new cardiovascular medicines
 
 -Zydus Research Centre Receives AAALAC Accreditation
 
 2010
 
 -CHL announces Bonus Shares in the ratio of 1:2
 
 - India unveiled its first indigenous H1N1 vaccine, which was
 developed by drug firm Cadila Healthcare and this vaccine will
 provide immunity from the H1N1 virus strain for one year.
 
 
 
 2011
 
 -Company has signed an Agreement with Bayer HealthCare to set up
 50:50 Joint Venture Company in the name of Bayer Zydus Pharma
 
 -Cadila gets USFDA nod for diabetes drug trial
 
 -Cadila Health acquires Bremer Pharma from ICICI Venture
 
 2012
 
 -Cadila Healthcare enters into a settlement and license agreement
 with Somaxon for Silenor
 
 -Cadila Healthcare gets USFDA nod for Aripiprazole orally
 disintegrating tablets
Source : Dion Global Solutions Limited
Quick Links for Cadila Healthcare
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.